Shiga toxin receptor Gb3Cer/CD77: Tumor-association and promising therapeutic target in pancreas and colon cancer

PLoS ONE

Volumn 4, Issue 8, 2009, Pages

  Distler, Ute ^a   Souady, Jamal ^a   Hülsewig, Marcel ^a   Drmić Hofman, Irena ^b   Haier, Jörg ^c   Friedrich, Alexander W ^a   Karch, Helge ^a   Senninger, Norbert ^c   Dreisewerd, Klaus ^a   Berkenkamp, Stefan ^d   Schmidt, M Alexander ^a   Peter Katalinić, Jasna ^a   Müthing, Johannes ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL SPLIT   (Croatia)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d Sequenom GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GLOBOTRIAOSYLCERAMIDE; LIPID; LONG CHAIN FATTY ACID; SHIGA TOXIN; SHORT CHAIN FATTY ACID; CERAMIDE TRIHEXOSIDE;

ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; MALIGNANT TRANSFORMATION; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ADENOCARCINOMA; CARBOHYDRATE ANALYSIS; CHEMISTRY; COLON TUMOR; METABOLISM; MOLECULAR GENETICS; PANCREAS TUMOR; THIN LAYER CHROMATOGRAPHY;

BACTERIA (MICROORGANISMS);

ADENOCARCINOMA; CARBOHYDRATE SEQUENCE; CHROMATOGRAPHY, THIN LAYER; COLONIC NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; PANCREATIC NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRIHEXOSYLCERAMIDES;

EID: 69949083601     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006813     Document Type: Article

References (58)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
2. Andre T, de Gramont A (2004) An overview of adjuvant systemic chemotherapy for colon cancer. Clin Colorectal Cancer 4: S22-28.
3. Ghaneh P, Costello E, Neoptolemos JP (2007) Biology and management of pancreatic cancer. Gut 56: 1134-1152.
4. Wilkinson N, Scott-Conner CE (2008) Surgical therapy for colorectal adenocarcinoma. Gastroenterol Clin North Am 37: 253-267.
5. Müthing J, Meisen I, Kniep B, Haier J, Senninger N, et al. (2005) Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acα2-6Galβ1-4GlcNAc-residues are receptors for the anticancer drug rViscumin. FASEB J 19: 103-105.
6. Durrant LG, Harding SJ, Green NH, Buckberry LD, Parsons T (2006) A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis. Cancer Res 66: 5901-5909.
7. Yin J, Hashimoto A, Izawa M, Miyazaki K, Chen GY, et al. (2006) Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res 66: 2937-2945.
8. Distler U, Souady J, Hülsewig M, Drmić-Hofman I, Haier J, et al. (2008) Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer. Mol Cancer Ther 7: 2464-2475.
9. Falguières T, Maak M, von Weyhern C, Sarr M, Sastre X, et al. (2008) Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther 7: 2498-2508.
10. Levery SB (2005) Glycosphingolipid structural analysis and glycosphingolipidomics. Methods Enzymol 405: 300-369.
11. Sonnino S, Prinetti A, Mauri L, Chigorno V, Tettamanti G (2006) Dynamic and structural properties of sphingolipids as driving forces for the formation of membrane domains. Chem Rev 106: 2111-2125.
12. Hakomori S (1996) Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 56: 5309-5318.
13. Miller-Podraza H, Lanne B, Angström J, Teneberg S, Milh MA, et al. (2005) Novel binding epitope for Helicobacter pylori found in neolacto carbohydrate chains: structure and cross-binding properties. J Biol Chem 280: 19695-19703.
14. Smith DC, Lord JM, Roberts LM, Johannes L (2004) Glycosphingolipids as toxin receptors. Semin Cell Dev Biol 15: 397-408.
15. Karch H, Tarr PI, Bielaszewska M (2005) Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 295: 405-418.
16. Kovbasnjuk O (2005) New insights into the role of Shiga toxins in intestinal disease. Gastroenterology 129: 1354-1355.
17. Tarr PI, Gordon CA, Chandler WL (2005) Shiga toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365: 1073-1086.
18. Kaper JB, Karmali MA (2008) The continuing evolution of a bacterial pathogen. Proc Natl Acad Sci 105: 4535-4536.
19. Dobrindt U (2005) (Patho-)Genomics of Escherichia coli. Int J Med Microbiol 295: 357-371.
20. Lingwood CA (1996) Role of verotoxin receptors in pathogenesis. Trends Microbiol 4: 147-153.
21. Müthing J, Schweppe CH, Karch H, Friedrich AW (2009) Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Thromb Haemost 101: 252-264.
22. Sandvig K (2001) Shiga toxins. Toxicon 39: 1629-1635.
23. Römer W, Berland L, Chambon V, Gaus K, Windschiegl B, et al. (2007) Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature 450: 670-675.
24. Yu M, Haslam DB (2005) Shiga toxin is transported from the endoplasmic reticulum following interaction with the luminal chaperone HEDJ/Erdj3. Infect Immun 73: 2524-2532.
25. Feizi T (1985) Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature 314: 53-57.
26. Farkas-Himsley H, Hill R, Rosen B, Arab S, Lingwood CA (1995) The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1. Proc Natl Acad Sci USA 92: 6996-7000.
27. + hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. Blood 94: 2901-2910.
28. Salhia B, Rutka JT, Lingwood C, Nutikka A, Van Furth WR (2002) The treatment of malignant meningioma with verotoxin. Neoplasia 4: 304-311.
29. Kovbasnjuk O, Mourtazina R, Baibakov B, Wang T, Elowsky C, et al. (2005) The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc Natl Acad Sci USA 102: 19087-19092.
30. Gehrmann M, Liebisch G, Schmitz G, Anderson R, Steinem C, et al. (2008) Tumor-specific Hsp70 plasma membrane localization is enabled by the glycosphingolipid Gb3. PLoS ONE 3: e1925.
31. Fredman P, Hedberg K, Brezicka T (2003) Gangliosides as therapeutic targets for cancer. BioDrugs 17: 155-167.
32. Johannes L, Decaudin D (2005) Protein toxins: intracellular trafficking for targeted therapy. Gene Ther 12: 1360-1368.
33. Janssen KP, Vignjevic D, Boisgard R, Falguières T, Bousquet G, et al. (2006) In vivo tumor targeting using a novel intestinal pathogen-based delivery approach. Cancer Res 66: 7230-7236.
34. Distler U, Hülsewig M, Souady J, Dreisewerd K, Haier J, et al. (2008) Matching IR-MALDI-o-TOF mass spectrometry with the TLC overlay binding assay and its clinical application for tracing tumor-associated glycosphingolipids in hepatocellular and pancreatic cancer. Anal Chem 80: 1835-1846.
35. Sobin LH, Wittekind C (2002) International Union Against Cancer (UICC) TNM Classification of Malignant Tumours, Ed. 6. New York: Wiley-Liss Inc. pp 272.
36. Smith HW, Linggood MA (1971) The transmissible nature of enterotoxin production in a human enteropathogenic strain of Escherichia coli. J Med Microbiol 4: 301-305.
37. Petric M, Karmali MA, Richardson S, Cheung R (1987) Purification and biological properties of Escherichia coli verotoxin. FEMS Microbiol Lett 41: 63-68.
38. Bielaszewska M, Friedrich AW, Aldick T, Schürk-Bulgrin R, Karch H (2006) Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clin Infect Dis 43: 1160-1167.
39. Müthing J, Duvar S, Heitmann D, Hanisch FG, Neumann U, et al. (1999) Isolation and structural characterization of glycosphingolipids of in vitro propagated human umbilical vein endothelial cells. Glycobiology 9: 459-468.
40. Meisen I, Friedrich AW, Karch H, Witting U, Peter-Katalinić J, et al. (2005) Application of combined high-performance thin-layer chromatography immunostaining and nanoelectrospray ionization quadrupole time-of-flight tandem mass spectrometry to the structural characterization of high- and low-affinity binding ligands of Shiga toxin 1. Rapid Commun Mass Spectrom 19: 3659-3665.
41. Chester MA (1999) IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). Nomenclature of glycolipids. Recommendations 1997. Glycoconj J 16: 1-6.
42. Müthing J (1998) TLC in structure and recognition studies of glycosphingolipids. In: Hounsell EF, editor. Methods in molecular biology, Volume 76: Glycoanalysis protocols. Totawa, NJ: Humana Press. pp 183-195.
43. Schweppe CH, Bielaszewska M, Pohlentz G, Friedrich AW, Büntemeyer H, et al. (2008) Glycosphingolipids in vascular endothelial cells: relationship of heterogeneity in Gb3Cer/CD77 receptor expression with differential Shiga toxin 1 cytotoxicity. Glycoconj J 25: 291-304.
44. Simons K, Ikonen E (1997) Functional rafts in cell membranes. Nature 387: 569-572.
45. Lundquist JJ, Toone EJ (2002) The cluster glycoside effect. Chem Rev 102: 555-578.
46. Chu KU, Ravindranath MH, Gonzales A, Nishimoto K, Tam WY, et al. (2000) Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma. Cancer 88: 1828-1836.
47. Kannagi R, Yin J, Miyazaki K, Izawa M (2008) Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants - Hakomori's concepts revisited. Biochim Biophys Acta 1780: 525-531.
48. Roque-Navarro L, Chakrabandhu K, de León J, Rodríguez S, Toledo C, et al. (2008) Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther 7: 2033-2041.
49. Thies A, Dautel P, Meyer A, Pfüller U, Schumacher U (2008) Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model. Br J Cancer 98: 106-112.
50. Stirpe F, Battelli MG (2006) Ribosome-inactivating proteins: progress and problems. Cell Mol Life Sci 63: 1850-1866.
51. Lencer WI, Saslowsky D (2005) Raft trafficking of AB5 subunit bacterial toxins. Biochim Biophys Acta 1746: 314-321.
52. Kiarash A, Boyd B, Lingwood CA (1994) Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. J Biol Chem 269: 11138-11146.
53. Lingwood CA (1999) Verotoxin/globotriaosyl ceramide recognition: angiopathy, angiogenesis and antineoplasia. Biosci Rep 19: 345-354.
54. Yang HJ, Hakomori SI (1971) A sphingolipid having a novel type of ceramide and lacto-N-fucopentaose 3. J Biol Chem 246: 1192-1200.
55. Hakomori SI, Nudelman E, Levery SB, Kannagi R (1984) Novel fucolipids accumulating in human adenocarcinoma. J Biol Chem 259: 4672-4680.
56. 6Cer). Carbohydr Res 178: 121-144.
57. Binnington B, Lingwood D, Nutikka A, Lingwood CA (2002) Effect of globotriaosyl ceramide fatty acid α-hydroxylation on the binding by verotoxin 1 and verotoxin 2. Neurochem Res 27: 807-813.
58. Kiguchi K, Iwamori Y, Suzuki N, Kobayashi Y, Ishizuka B, et al. (2006) Characteristic expression of globotriaosyl ceramide in human ovarian carcinoma-derived cells with anticancer drug resistance. Cancer Sci 97: 1321-1326.